Basiliximab
CD25 | |
---|---|
Clinical data | |
Trade names | Simulect |
AHFS/Drugs.com | Monograph |
MedlinePlus | a612013 |
License data |
|
Pregnancy category |
|
Immunosuppressants | |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | 7.2 days |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C6378H9844N1698O1997S48 |
Molar mass | 143801.68 g·mol−1 |
(what is this?) (verify) |
Basiliximab, sold under the brand name Simulect, is a
The most common side effects (seen in more than 20% of patients) include constipation, urinary tract infections (infection of the structures that carry urine), pain, nausea (feeling sick), peripheral oedema (swelling), hypertension (high blood pressure), anemia (low red blood cell counts), headache, hyperkalaemia (high blood potassium levels), hypercholesterolaemia (high blood cholesterol levels), surgical wound complication, weight increase, increased serum creatinine (a marker of kidney problems), hypophosphataemia (low blood phosphate levels), diarrhea and upper respiratory tract infection (colds).[3]
Basiliximab was approved for medical use in the United States and in the European Union in 1998.[2][3][4]
Medical uses
Basiliximab is
Basiliximab is an
Mechanism of action
Basiliximab competes with IL-2 to bind to the alpha chain subunit of the IL2 receptor on the surface of the activated T lymphocytes and thus prevents the receptor from signaling. This prevents T cells from replicating and also from activating B cells, which are responsible for the production of
Chemistry
It is a chimeric CD25 monoclonal antibody of the IgG1 isotype.[7][8]
History
It is a Novartis product and was approved by the Food and Drug Administration (FDA) in 1998.[9]
References
- FDA. Retrieved 22 October 2023.
- ^ a b c d e "Simulect- basiliximab injection, powder, for solution". DailyMed. 6 October 2022. Archived from the original on 6 October 2022. Retrieved 27 February 2023.
- ^ a b c d e f g "Simulect EPAR". European Medicines Agency. Archived from the original on 11 January 2022. Retrieved 27 February 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Basiliximab Product Approval Information - Licensing Action". U.S. Food and Drug Administration (FDA). 20 February 2009. Archived from the original on 13 January 2017. Retrieved 27 February 2023.
- ^ MedlinePlus. Last Revised - 15 June 2012 Basiliximab Injection Archived 5 July 2016 at the Wayback Machine
- ISBN 3-540-00878-0.
- ^ S2CID 3296555.
- ^ a b "Basiliximab label" (PDF). Food and Drug Administration. Archived (PDF) from the original on 22 February 2017. Retrieved 16 December 2019.
- from the original on 13 April 2021. Retrieved 5 June 2020.